| Product Name:Budesonide |
 |
| Molecular Formula:C25H34O6 |
 |
| CAS:51333-22-3 |
 |
Product Name:Budesonide
Another Name:16α,17-[(1RS)-butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4-diene-3,20-dione
CAS:51333-22-3
Molecular Weight:430.53
Molecular Formula:C25H34O6
Budesonide
ALIAS:16α,17-[(1RS)-butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4-diene-3,20-dione
CAS NO.:51333-22-3
Formula:C25H34O6
Molecular Weight:430.53
Quality Standard: EP
pharmacological effects of this product is a highly efficient local anti-inflammatory effects of glucocorticoids. Decreased release of the active medium, it can enhance the endothelial cells, smooth muscle cells and lysosomal membrane stability, suppression of the immune response and reduce antibody synthesis, so that the histamine and other allergic and decreased activity, and can reduce the enzymes stimulate antigen-antibody binding promoting process, inhibiting the synthesis and release of bronchoconstrictor substances to alleviate smooth muscle contraction reaction. Acute, sub-acute and long-term toxicity studies found that the systemic effects of the products, such as weight loss, lymphoid tissues and adrenal cortical atrophy, weaker than other corticosteroids or equivalent.
Ms. Julia ycgc_int04@yccreate.com
|
 |
Product Name:Budesonide
Another Name:16α,17-[(1RS)-butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4-diene-3,20-dione
CAS:51333-22-3
Molecular Weight:430.53
Molecular Formula:C25H34O6
Budesonide
ALIAS:16α,17-[(1RS)-butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4-diene-3,20-dione
CAS NO.:51333-22-3
Formula:C25H34O6
Molecular Weight:430.53
Quality Standard: EP
pharmacological effects of this product is a highly efficient local anti-inflammatory effects of glucocorticoids. Decreased release of the active medium, it can enhance the endothelial cells, smooth muscle cells and lysosomal membrane stability, suppression of the immune response and reduce antibody synthesis, so that the histamine and other allergic and decreased activity, and can reduce the enzymes stimulate antigen-antibody binding promoting process, inhibiting the synthesis and release of bronchoconstrictor substances to alleviate smooth muscle contraction reaction. Acute, sub-acute and long-term toxicity studies found that the systemic effects of the products, such as weight loss, lymphoid tissues and adrenal cortical atrophy, weaker than other corticosteroids or equivalent.
Ms. Julia ycgc_int04@yccreate.com
|
|
|
|
|
